Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC-CIK + Chemotherapy in Resected Esophageal Cancer
NCT02644863Phase 2Unknown
- Sponsor
- Shenzhen Hornetcorn Biotechnology Co., Ltd.
- Start
- Dec 2015
- Primary completion
- Dec 2018
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dendritic cell vaccine + cytokine-induced killer cells in esophageal cancer (2 arms), sponsored by Shenzhen Hornetcorn Biotechnology Co., Ltd. Primary endpoint: Overall Survival at 3 years. Status: unknown.
02
Drugs
dendritic cell vaccine + cytokine-induced killer cells
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT02644863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02644863.